Adlai Nortye Ltd. (“Adlai Nortye”) and Xiamen Biotime Biotechnology Co., Ltd. (“Biotime”) Announce Technical and Commercial Partnership on PD-L1 Inhibitors, Anti-hTNFR2 Antibody Products and Many Other Products

Adlai Nortye Biopharma Co., Ltd. a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with R&D and global clinical operation centers in both China and the United States, has expanded its technical and commercial partnership with Xiamen Biotime Biotechnology Co., Ltd. a Hi-Tech enterprise that specialized in R&D, production, and sales of POCT in vitro diagnostic devices and reagents, and offer the industry’s most comprehensive in vitro diagnostics solutions to more than 60 countries and regions.

The agreement aims to boost the development, production and commercialization of the PD-L1 inhibitors AN4005, anti-hTNFR2 antibody products and other products in Greater China and other regions of the world. Under the deal, the total amount of investment has reached several hundreds of millions of yuan which includes the down payment, the milestone payment that triggered by the milestone events and the royalties.

The AN4005 Adlai Nortye developed is a drug candidates that made the fastest progress in clinical trials. It shows strong anti-tumour efficacy, good multibinding, high safety and meets clinical and commercial needs，in addition to that, it also shows great potential and might pioneer oral small-molecule inhibitor of PD-L1. AN3025 is a new humanized IgG1anti-hTNFR2 antibody which is in the early part of development of preclinical trial, it’s expected to enhance antitumor immune response which may help to achieved better tumour control and improve treatment.

“Indigenous innovation is the core to Biotime, we just create a new business of innovative medicine, increase the research and development funding, take part in the innovative network and try to be a high-quality developer, innovative engineer to the industry.” said Yu Jianping, Executive Secretary of Biotime. “Adlai Nortye is a leading brand of innovative medicine, so this cooperation would be a win-win prospect.”

“We are glad to come to an agreement with Biotime who has well-grounded research and technical capabilities, they continue to pursue innovation-driven development and highly value product research. Partnership is expected to begin the process profit-oriented, development of AN4005, AN3025 and other products across the globe. We are confident these products would benefit all the patient in the world and the cooperation would only accelerate the actions we are going to take.” said He Nanhai, Ph.D., Head of Adlai Nortye’s global R&D.

About Biotime

Established in April 2008, Xiamen Biotime is a Hi-tech enterprise that specialized in R&D, production, and sales of POCT in vitro diagnostic devices and reagents. Biotime has successfully settled the mature medical marketing channels during the past years. With the leading technologies, Biotime aims to develop superior IVD products that provide better solutions for health care and benefit people from all over the world. Besides immunofluorescence, Biotime also developed other technological platforms, which includes Chemiluminescence, Electrochemistry, HPLC and colloidal gold, etc. After the outbreak of COVID-19, Biotime actively took actions to fight against the pandemic and successfully researched and developed COVID-19 related products, during the period, Biotime has obtained 20+ registration certificates including FDA EUA, CE, CIBG etc. Furthermore, we conducted performance verification in foreign authoritative institutions and got brilliant evaluation results from Barts Health in the UK, Amiens University Medical Centre in France, HUS LAB Diagnostic Centre in Finland, etc.